Colorectal cancer: observed 5-year DFS with/without 5FU-based adjuvant therapy
Using the end point of 5-year DFS, the model was evaluated for discriminating ability, calibration and over-fitting. The calibration of the model was assessed by comparing the predicted 5-year DFS rates for surgery alone and for surgery plus adjuvant therapy with the corresponding observed or Kaplan-Meier estimate probabilities.
Results are presented as % patients still alive at 5 years with 95% confidence interval and group size.
Low grade patients
Group |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
73 - [69 - 77], N=587 |
79 - [75 - 82], N= 597 |
6 |
0 nodes & T4 |
69 - [54 - 87], N= 33 |
72 - [58 - 89], N= 36 |
3 |
1-4 nodes & T1-2 |
72 - [62 - 84], N= 65 |
88 - [81 - 96], N= 71 |
16 |
1-4 nodes & T3 |
46 - [41 - 51], N= 464 |
64- [59 - 68], N= 496 |
18 |
1-4 nodes & T4 |
33 - [20 - 54], N= 37 |
56 - [38 - 81], N= 24 |
23 |
5+ nodes & T1-2 |
29 - [12 - 68], N= 14 |
44 - [25 - 78], N= 17 |
15 |
5+ nodes & T3 |
26 - [20 - 36], N= 128 |
48 - [40 - 57], N= 142 |
22 |
5+ nodes & T4 |
10 - [2 - 65], N= 10 |
24 - [7 - 81], N=8 |
14 |
High grade patients
Group |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain* (%) |
|---|---|---|---|
0 nodes & T3 |
66 - [56 - 78], N= 88 |
62 - [51 - 75], N= 76 |
-4 |
0 nodes & T4 |
57 - [32 - 100], N= 10 |
46 - [25 - 87], N= 13 |
-11 |
1-4 nodes & T1-2 |
46 - [23 - 73], N= 11 |
72 - [47 - 100], N= 9 |
26 |
1-4 nodes & T3 |
52 - [43 - 64], N= 99 |
57 - [48 - 68], N= 95 |
5 |
1-4 nodes & T4 |
19 - [7 - 54], N= 20 |
61 - [35 - 100], N= 9 |
42 |
5+ nodes & T1-2 |
40 - [13 - 100], N= 6 |
25 - [5 - 100], N= 4 |
-15 |
5+ nodes & T3 |
12 - [7 - 81], N= 49 |
26 - [18 - 39], N= 74 |
14 |
5+ nodes & T4 |
39 - [18 - 85], N=10 |
* Number of patients in that column averaged more than five imputed data sets.
Reprinted with permission. ©2008 American Society of Clinical Oncology. All rights reserved. Gill S et al: Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J Clin Oncol Vol.22 (10), 2004: 1797-1806.